Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementiaName : Spomenka Kidemet-Piskac
Affliation : PhD scholar
University : General Hospital Varazdin, Ivana Mestrovica bb
Country : Croatia
Aim To determine if the use of sensitive and specific biomarkers such as phosphorylated tau proteins could contribute to an earlier and more accurate diagnosis of both Alzheimer’s disease (AD) and vascular dementia (VaD). Diagnosis of either AD or VaD is still largely based on clinical guidelines and exclusion of other diseases that may lead to dementia.
Methods A total of 202 patients, of which 152 patients with AD, 28 patients with VaD, and 18 healthy control (HC), cognitively normal subjects were included. We analyzed cerebrospinal fluid (CSF) levels of total protein (t-tau), tau protein phosphorylated at threonine 231 (p-tau231), and factor score (FS) determined by combination of p-tau231 and MMSE in patients with AD and VaD, as well as in HC. We tested the diagnostic accuracy of these biomarkers in the CSF and FS (p-tau231, MMSE) in differentiating AD from VaD and HC.
Results Total tau levels were statistically significantly elevated in subjects with AD compared to HC subjects, as well as in VaD+AD and VaD subjects compared to HC subjects. P-tau231 levels were statistically significantly higher in AD patients versus HC as well in patients with VaD versus HC. P-tau231 levels did not distinguish AD from VaD patients. Importantly, FS (p-tau231 and MMSE) showed statistically significant differences in the distribution of subjects with AD and VaD..
Conclusion These results indicate that FS (p-tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD.